Chen C H, Hsu T L, Lin S J, Ting C T, Chou P, Wang S P, Yin F C, Chang M S
Division of Cardiology, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jul;56(1):12-22.
Benazepril hydrochloride is a non-sulfhydryl-containing, angiotensin-converting enzyme (ACE) inhibitor. The short-term and long-term antihypertensive effects of benazepril remain to be established in Chinese.
Hypertensive subjects with diastolic blood pressure 95-110 mmHg, after two week placebo run-in first, entered a four-week double-blind phase with treatment of benazepril 10 mg once daily or captopril 25 mg three times daily, then received one-year open treatment of benazepril 10 mg daily with or without diuretics. Ambulatory blood pressure monitoring was performed at the end of placebo run-in, after four-week double-blind phase, and after one-year open treatment.
Of the 75 subjects (41 male, 34 female, mean age 57 +/- 12 years, range 34-88 years) who completed the double-blind phase, 42 subjects finished the one-year extension phase. Reasons for withdrawal from the study included irritable cough (16, 21%), hypotension (1, 1%), and poor compliance (16, 21%). During the short-term double-blind phase, benazepril reduced clinic and mean 24-h ambulatory blood pressure by -21/-10 mmHg and by -17/-10 mmHg respectively, and captopril by -21/-13 mmHg and by -17/-10 mmHg respectively. After one-year open treatment by benazepril for the 42 subjects, the one-year average clinic blood pressure was 134/88 mmHg (155/104 mmHg at entry and 135/93 mmHg at the end of the double-blind phase), and the mean 24-h ambulatory blood pressure was 137/87 mmHg (149/95 mmHg at entry and 132/84 mmHg at the end of the double-blind phase).
The antihypertensive effect of benazepril 10 mg daily with or without diuretics is not significantly different from that of captopril 75 mg daily in the short-term and can reasonably be maintained for one year.
盐酸贝那普利是一种不含巯基的血管紧张素转换酶(ACE)抑制剂。贝那普利的短期和长期降压效果在中国仍有待确定。
舒张压为95 - 110 mmHg的高血压患者,首先经过两周安慰剂导入期后,进入为期四周的双盲阶段,接受每日一次10 mg贝那普利或每日三次25 mg卡托普利治疗,然后接受为期一年的开放治疗,每日服用10 mg贝那普利,可联合或不联合利尿剂。在安慰剂导入期结束时、四周双盲阶段结束后以及一年开放治疗后进行动态血压监测。
在完成双盲阶段的75名受试者(41名男性,34名女性,平均年龄57±12岁,范围34 - 88岁)中,42名受试者完成了一年的延长期。退出研究的原因包括刺激性咳嗽(16例,21%)、低血压(1例,1%)和依从性差(16例,21%)。在短期双盲阶段,贝那普利使诊所血压和24小时平均动态血压分别降低-21/-10 mmHg和-17/-10 mmHg,卡托普利分别降低-21/-13 mmHg和-17/-10 mmHg。42名受试者接受贝那普利一年开放治疗后,一年平均诊所血压为134/88 mmHg(入组时为155/104 mmHg,双盲阶段结束时为135/93 mmHg),24小时平均动态血压为137/87 mmHg(入组时为149/95 mmHg,双盲阶段结束时为132/84 mmHg)。
每日服用10 mg贝那普利联合或不联合利尿剂的降压效果在短期内与每日服用75 mg卡托普利的效果无显著差异,且可合理维持一年。